Severens Johan L

van Gestel Aukje, Webers Carroll A B, Beckers Henny J M, Peeters Andrea, Severens Johan L, Schouten Jan S A G

This study modeled ocular hypertension, finding the 15-year risk of unilateral blindness is under 10% for both treated and untreated patients, informing clinical management decisions.

van Gestel Aukje, Schouten Jan S A G, Beckers Henny J M, Severens Johan L, Hendrikse Fred, Webers Carroll A B

Studying ocular hypertension, early pressure-lowering treatment was found to be more effective and cheaper long-term than delayed treatment, making it a dominant, cost-effective strategy.

Peeters Andrea, Schouten Jan S A G, Severens Johan L, Hendrikse Fred, Prins Martin H, Webers Carroll A B

This study found starting ocular hypertension treatment with timolol was more cost-effective than latanoprost for preventing blindness, due to latanoprost's higher cost.

van Gestel Aukje, Webers Carroll A, Severens Johan L, Beckers Henny J, Jansonius Nomdo M, Hendrikse Fred et al.

This study found that a low target intraocular pressure and initial prostaglandin analogue therapy are cost-effective for primary open-angle glaucoma, while visual field testing frequency impacts health gains and costs.